Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study

Magin, Parker; Juratowitch, Laura; Dunbabin, Janet; McElduff, Patrick; Goode, Susan; Tapley, Amanda; Pond, Dimity

doi:10.1002/gps.4335

Cited by 14 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lawrence and colleagues observed that diagnostic confirmation was an important incentive for participation among cognitively impaired older adults [40]. Findings are nevertheless inconsistent [44,45]. Although a perceived high risk of AD was associated with increased interest in receiving information about one's genetic and/or diagnostic status [46], the opposite was true for individuals with self-reported cognitive complaints or family history of AD [46] and former caregivers of AD patients [40].…”

Section: Discussionmentioning

confidence: 99%

Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial

et al. 2020

View full text Add to dashboard Cite

Background: A better insight into older adults' understanding of and attitude towards cognitive disorders and their prevention, as well as expectations and reasons for participation in prevention trials, would help design, conduct, and implement effective preventive interventions. This qualitative study aimed at exploring the knowledge and perceptions of cognitive disorders and their prevention among participants in a prevention trial. Methods: Semi-structured interviews were conducted among the participants of a multinational randomised controlled trial testing the efficacy of a lifestyle-based eHealth intervention in preventing cardiovascular disease or cognitive decline in community dwellers aged 65+. Participants were probed on their reasons for participation in the trial and their views on general health, cardiovascular disease, ageing, and prevention. The subset of data focusing on cognitive disorders (15 interviewees; all in Finland) was considered for this study. Data were analysed using content analysis. Results: Participants' knowledge of the cause and risk factors of cognitive disorders and prevention was limited and superficial, and a need for up-to-date, reliable, and practical information and advice was expressed. Cognitive disorders evoked fear and concern, and feelings of hopelessness and misery were frequently expressed, indicating a stigma. Strong heredity of cognitive disorders was a commonly held belief, and opinions on the possibility of prevention were doubtful, particularly in relation to primary prevention. Family history and/or indirect experiences of cognitive disorders was a recurrent theme and it showed to be linked to both the knowledge of and feelings associated with cognitive disorders, as well as attitude towards prevention. Indirect experiences were linked to increased awareness and knowledge, but also uncertainty about risk factors and possibility of prevention. Distinct fear and concerns, particularly over one's own cognition/risk, and high motivation towards engaging in prevention and participating in a prevention trial were also identified in connection to this theme.

show abstract

Section: Discussionmentioning

confidence: 99%

Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We found that it was most common to measure biomarkers at 2 points in time, with very few studies repeating measures more than twice. This can be attributed to the high costs of the measures used [ 20 ] or the invasiveness of CSF sample collection [ 140 ]. Earlier and more frequent measures would facilitate more robust conclusions to be drawn on the precise timing and etiology of AD pathology.…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers

Lawrence

Vegvari

Ower

et al. 2017

JAD

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disease, with no effective treatment or cure. A gold standard therapy would be treatment to slow or halt disease progression; however, knowledge of causation in the early stages of AD is very limited. In order to determine effective endpoints for possible therapies, a number of quantitative surrogate markers of disease progression have been suggested, including biochemical and imaging biomarkers. The dynamics of these various surrogate markers over time, particularly in relation to disease development, are, however, not well characterized. We reviewed the literature for studies that measured cerebrospinal fluid or plasma amyloid-β and tau, or took magnetic resonance image or fluorodeoxyglucose/Pittsburgh compound B-positron electron tomography scans, in longitudinal cohort studies. We summarized the properties of the major cohort studies in various countries, commonly used diagnosis methods and study designs. We have concluded that additional studies with repeat measures over time in a representative population cohort are needed to address the gap in knowledge of AD progression. Based on our analysis, we suggest directions in which research could move in order to advance our understanding of this complex disease, including repeat biomarker measurements, standardization and increased sample sizes.

show abstract

“…Patients themselves have a range of views about this, and a large minority are not keen to be diagnosed with dementia. 3 Indeed, the diagnosis is a grim one of a terminal illness with progressive deterioration. However, as with other terminal illnesses, it may be helpful for a person to know what is happening: while they still have capacity, they can complete their advance care planning (will, appointment of health and financial spokespeople, advance care directive), fulfil 'bucket list' plans and perhaps access anti-dementia medications and implement diet and exercise interventions to slow progression.…”

Section: Why Assess Cognitive Impairment?mentioning

confidence: 99%

Office-based assessment of cognitive impairment

Pond

2018

Aust J Gen Pract

Self Cite

View full text Add to dashboard Cite

Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study

Abstract: This study demonstrates that a majority of patients would like to know if they have AD. Acceptability of testing modalities, however, varies. Noninvasive, familiar methods are more acceptable.

Cited by 14 publications

References 36 publications

Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial

Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial

A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers

Office-based assessment of cognitive impairment

Contact Info

Product

Resources

About